TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05514015
Drug: rituximab combined with corticosteroids
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;
Study: NCT05514015
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
Study: NCT05831878
Drug: Disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0mg/kg, iv, day1, every 2 weeks
Study: NCT05256108
Drug: Oxycodone 40 mg
Normalized name: oxyCODONE 40 mg oral tablet, extended release
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
Study: NCT05256108
Drug: Tramadol 600 mg
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
Study: NCT05256108
Drug: Cebranopadol 600 µg
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Study: NCT05523102
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous paracetamol/acetaminophen
Study: NCT06261489
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
Study: NCT06261489
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
Study: NCT05256108
Drug: Cebranopadol 1000 µg
Normalized name: menthol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Study: NCT05790681
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
Study: NCT05976997
Drug: Duvelisib, Chidamide
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
Study: NCT04676477
Drug: HER3-DXd
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
Study: NCT04676477
Drug: HER3-DXd
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Study: NCT04676477
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration at 40 mg or 80 mg once daily
Study: NCT04676477
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Study: NCT04676477
Drug: HER3-DXd
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion 5.6 mg/kg Q3W
Study: NCT04676477
Drug: HER3-DXd
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion 4.8 mg/kg Q3W
Study: NCT04676477
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration at 80 mg once daily
Study: NCT06530550
Drug: PI3K inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
Study: NCT05969041
Drug: MT-302 (A)
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-302 is an investigational drug
Study: NCT05531123
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg I.V. Q3W on the day 1
Study: NCT05531123
Drug: gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
Study: NCT05631717
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
Study: NCT05673980
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
Study: NCT05264038
Drug: OC514 (Low dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose level of OC514
Study: NCT05264038
Drug: OC514 (High dose)
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose level of OC514
Study: NCT06067256
Drug: Female Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effimia® exerts its action by means of a gonadotropin suppression mechanism through the estrogenic and progestin action exerted by EE and NGM. The contraceptive effect of Effimia® is based on the interaction of various factors, the most important of which consist of ovulation inhibition and endometrial modifications.
Study: NCT06119893
Drug: submucosal 8 mg (2 mL) dexamethasone application
Normalized name: dexamethasone 2 MG/ML
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
Study: NCT06119893
Drug: submucosal 2 mL 0.9% isotonic sodium chloride application
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
Study: NCT05446324
Drug: Gallium-68-tilmanocept
Normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
Study: NCT06439550
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, q3w
Study: NCT06439550
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First dose 8mg/kg, maintenance 6mg/kg, q3w
Study: NCT06439550
Drug: Oxaliplatin + Tegafur
Normalized name: tegafur
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
Study: NCT04864067
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation Chemotherapy
Study: NCT04864067
Drug: 5-Fluoracil
Normalized name: 5-Fluoracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation Chemotherapy
Study: NCT05707273
Drug: Autologous Anti-CD19 CAR-expressing T Lymphocytes
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05707273
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05927012
Drug: KER-047
Normalized name: KER-047
DrugBank: KER-047 (DB19111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, daily (or every other day) administration
Study: NCT05183139
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules
Study: NCT05183139
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide capsules
Study: NCT05183139
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsules
Study: NCT05183139
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets
Study: NCT05186012
Drug: APG-1252
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
Study: NCT05186012
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 30mg orally BIW. Every 28 days as a cycle.
Study: NCT05809869
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
Study: NCT05809869
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 300mg intravenous infusion on week 1 only.
Study: NCT05244057
Drug: Tenofovir Alafenamide Tablets
Normalized name: Tenofovir Alafenamide Tablets
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25mg, p.o., qd for 48 weeks
Study: NCT05244057
Drug: Pegylated Interferon alfa 2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90ug, s.c., qw for 48 weeks
Study: NCT04280692
Drug: Sulfadoxine-Pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-curative 500mg/25mg single dose regimen
Study: NCT04280692
Drug: Piperaquine
Normalized name: Piperaquine
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sub-curative 480mg single dose regimen
Study: NCT04280692
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single low dose regimen 0.25 mg base/kg
Study: NCT06476301
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
Study: NCT06058546
Drug: low dose Jiuweihuaban Pill
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Study: NCT06058546
Drug: high dose Jiuweihuaban Pill
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Study: NCT05477264
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.
Study: NCT05176821
Drug: esomeprazole plus amoxicillin
Normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
Study: NCT05176821
Drug: amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
Study: NCT06577961
Drug: Vorolanib
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
Study: NCT06577961
Drug: cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
Study: NCT05480072
Drug: Palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21
Study: NCT05745818
Drug: Colchicine Pill
Normalized name: colchicine Pill
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral pills
Study: NCT06214195
Drug: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
Normalized name: Trimo San
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
Study: NCT05029037
Drug: Dextrose 500 mL
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days.
Study: NCT06525350
Drug: Glumetinib tablets
Normalized name: selumetinib
DrugBank: Glumetinib (DB15630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
Study: NCT06525350
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A chemotherapy drug
Study: NCT05463757
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
Study: NCT05463757
Drug: Sonidegib
Normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
Study: NCT06156995
Drug: Oral Mosapride Tablets
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
Study: NCT05876806
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
Study: NCT05876806
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
Study: NCT04667637
Drug: edaravone dexborneol
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
Study: NCT05505591
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
Study: NCT04447898
Drug: PPV-06 10 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study: NCT05736757
Drug: Tissue Plasminogen Activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
Study: NCT04447898
Drug: PPV-06 50 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study: NCT04565145
Drug: Kava Dietary Supplement
Normalized name: KAVA
DrugBank: Kava (DB01322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given three 75mg kava capsules per day for one week
Study: NCT05635357
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole claim is used as the exposure group.
Study: NCT06323824
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Methadone~Possible formulations:~10 and 40 mg tablets
Study: NCT06323824
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)
Study: NCT06578546
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.
Study: NCT06578546
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.
Study: NCT06578546
Drug: Orebatinib
Normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
Study: NCT05635357
Drug: Exemestane/Letrozole
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane/Letrozole claim is used as the reference group.
Study: NCT04735510
Drug: cyclosporine ophthalmic emulsion 0.05%
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive restasis
Study: NCT04118387
Drug: Acetazolamide + supplemental oxygen + PAP therapy
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
Study: NCT06388135
Drug: Serplulimab Combined With Nab-paclitaxel and Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
Study: NCT06388135
Drug: nab-paclitaxel，Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nab-paclitaxel，Cisplatin